About Us

GEUS Technology

Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.


The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.

Latest News

World CLL Day 2023

Chronic Lymphocytic Leukemia (CLL) affects countless lives, making it the most prevalent form of leukemia in adults, impacting both blood and bone marrow. On the 1st of September, we join …

Aniling at the CataloniaBio & HealthTech BBQ 2023

We were thrilled to once again be a part of the BBQ2023 event organized by CataloniaBio & HealthTech. Yesterday’s gathering provided an exceptional platform for fostering connections and reuniting with colleagues and …